Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab in Homozygous Familial Hypercholesterolemia (CREDIT-3)
NCT04031742Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tafolecimab in homozygous familial hypercholesterolemia (HoFH), sponsored by Innovent Biologics. Started Sep 2019; status: completed.
02
Drugs
tafolecimab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT04031742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04031742.